… In the present study, the pooled median PFS and OS for neoadjuvant EGFR-TKIs in the
stage IIIA group were 13.2 and 41.9 months, respectively, but median PFS values varied …

… In this study, the 5-year OS rates for p-stage II EGFR-Mt and p-stage IIIA EGFR-Mt were 92.0…
EGFR mutation was not an independent prognostic factor for OS of patients with p-stage IIIA …

… Univariate analysis showed SUV, lymphovascular invasion, pleural invasion, intrapulmonary
metastasis, LN metastasis, pStage IIA–IIIA, and positive EGFR mutation status were risk of …

… inhibitor (EGFR TKI) therapy is the standard of care for lung cancer patients with sensitising
EGFR mutations (exon 19 deletion or L858R mutation). Several phase III studies have …

… stage III NSCLC were treated with consolidation durvalumab. Of these patients, 14 had tumor
mutations in the ERBB family including 11 EGFR … of ERBB2/EGFR-mutant stage III NSCLC. …

… stage III NSCLC who have not progressed after chemoradiotherapy, on the basis of data from
the phase 3 … of immunotherapy in patients with stage III EGFR-mutant (EGFRm) NSCLC is …

The ADJUVANT study reported the comparative superiority of adjuvant gefitinib over
chemotherapy in disease-free survival of resected EGFR-mutant stage II–IIIA non-small cell lung …

… In the phase 2 EVAN trial, Chinese patients with resected stage IIIA EGFRm NSCLC were
randomly assigned to either erlotinib or vinorelbine plus cisplatin chemotherapy. Furthermore, …

… have shown that neoadjuvant EGFR-TKI therapy results in N2 downstaging in patients …
stage IIIA-N2 NSCLC harboring EGFR mutation [9–12]. In two phase II studies, neoadjuvant EGFR…

… EGFR mutation status for erlotinib in a phase III trial from China (OPTIMAL) showed similar
results to IPASS. There have been no completed phase III … analyses of EGFR mutation testing …